MELA Sciences to Host Analyst Meeting and Webcast on Wednesday, August 13 in New York City

        Print
| Source: MELA Sciences

IRVINGTON, N.Y., Aug. 7, 2014 (GLOBE NEWSWIRE) -- MELA Sciences, Inc. (Nasdaq:MELA), developer of the MelaFind® system, an optical diagnostic device approved for use in the U.S. and the European Union to assist dermatologists in melanoma diagnosis, will host an analyst breakfast on Wednesday, August 13, 2014 from 8:00 a.m. to 9:30 a.m. Eastern time in New York City. The event will feature a presentation by Darrell S. Rigel, MD, a Clinical Professor of Dermatology at NYU Langone Medical Center. Rose Crane, President and CEO of MELA Sciences, will also provide an overview of the Company as well as its lead product, the MelaFind System.

Darrell S. Rigel is a Clinical Professor of Dermatology at NY Langone Medical Center. His research is in the areas of risk factors and prognosis for malignant melanoma and other skin cancers and factors leading to aging of the skin. He has published numerous articles in peer-reviewed journals and is lead editor of "Cancer of the Skin." He has served as President of the American Academy of Dermatology, American Society for Dermatologic Surgery and American Dermatological Association. He is also a member of MELA Sciences' Scientific Advisory Committee.

Attendance at the Analyst Breakfast is limited to institutional investors and sell side analysts. To reserve a space, please contact Veronica Molina at LifeSci Advisors at 646-597-6979.

The presentations and the question-and-answer session will be webcast live and archived on the Investor Relations section of MELA Sciences' website at www.melasciences.com.

About MELA Sciences, Inc. www.melasciences.com

MELA Sciences is a medical technology company dedicated to designing and developing innovative software-driven technology for the clinical early detection and prevention of skin cancer. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature.

Media
Diana Garcia Redruello
MELA Sciences, Inc.
212-518-4226


Investors
Andrew McDonald
LifeSci Advisors, LLC
646-597-6987